Apyx Medical shares surge 12.33% after-hours as preliminary Q4 revenue hits $19M, driven by 51% U.S. Surgical Aesthetics growth post-AYON launch.

Apyx Medical (APYX) surged 12.33% in after-hours trading following the announcement of preliminary Q4 2025 revenue growth driven by a 51% year-over-year increase in U.S. Surgical Aesthetics segment revenue, attributed to the successful commercial launch of its AYON Body Contouring System. The company reported total Q4 revenue of $19.0–$19.2 million, a 34% YoY rise, with full-year 2025 revenue expected to reach $52.7–$52.9 million, up 10% YoY. CEO Charlie Goodwin highlighted AYON’s market adoption and the impact of GLP-1 therapies on demand for aesthetic procedures due to post-weight-loss skin laxity. The positive results underscored the company’s strategic positioning in the surgical aesthetics sector and reinforced confidence in its growth trajectory.